Sigma-Tau Pharmaceuticals, Inc. Launches New Corporate Web Site

Share Article

Sigma-Tau Pharmaceuticals, Inc. is dedicated to providing new therapies and new hope for patients with rare diseases. There are some 6,000 identified rare diseases that affect approximately 10 million patients in the United States. The founding principle and core belief of Sigma-Tau Pharmaceuticals, Inc., a wholly owned subsidiary of Sigma-Tau S.p.A., is that finding therapies for rare diseases is just as important as finding ones for more common diseases. After all, to the patient, there’s nothing “rare” about their condition.

Sigma-Tau Pharmaceuticals, Inc. announced today that the company has launched its new corporate web site at http://www.sigmatau.com.

Sigma-Tau Pharmaceuticals, Inc. is dedicated to providing new therapies and new hope for patients with rare diseases. There are some 6,000 identified rare diseases that affect approximately 10 million patients in the United States. The founding principle and core belief of Sigma-Tau Pharmaceuticals, Inc., a wholly owned subsidiary of Sigma-Tau S.p.A., is that finding therapies for rare diseases is just as important as finding ones for more common diseases. After all, to the patient, there’s nothing “rare” about their condition.

To that end, Sigma-Tau Pharmaceuticals has been focused on rare diseases since its founding, and was one of the first companies to obtain an Orphan Drug Designation in the United States more than 20 years ago.

Our core belief is that no patient should go untreated simply because the disease they are fighting is so rare that only a few thousand, or even a few hundred, suffer from the condition. Every one of us shares an unwavering commitment to develop novel products and therapies for patients with rare diseases. This unique vision, indeed, our passion, is woven into everything we do.

From our people, to our pipeline, to our partners, and most importantly, to our patients, Sigma-Tau Pharmaceuticals is dedicated to the relentless pursuit of creating treatments for rare diseases.

Sigma-Tau Pharmaceuticals, Inc., a wholly owned U.S. subsidiary of Sigma-Tau S.p.A., is particularly proud of its research in the area of rare diseases. For additional information about the company, please visit http://www.sigmatau.com. If you need to contact us for further information, please call 1-800-447-0169 and ask for the Marketing Group.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Yamil Hernandez
Visit website